Dayvigo (Lemborexant) Cost in Ohio: Prices, Insurance, and Savings in 2026

Dayvigo is the brand name for lemborexant, an FDA-approved oral dual orexin receptor antagonist (DORA) prescribed for insomnia in adults, taken as a 5 mg or 10 mg tablet once nightly. It is a Schedule IV controlled substance, distinct from the older DORA suvorexant (Belsomra) and from GABA-modulating hypnotics like zolpidem (Ambien) or doxepin (Silenor).

For an Ohio reader, the useful question is not "what does Dayvigo cost" but "which coverage pathway applies to me, since that determines the price far more than which pharmacy I choose." Cash price, insurance tier, Medicaid exclusion, manufacturer assistance, and compounding are separate systems with separate rules, and mixing them up is the most common way patients overpay or give up too early.

The core answer, and its limits

Dayvigo's out-of-pocket cost in Ohio depends almost entirely on which of four pathways applies to a given patient: commercial insurance with prior authorization, Ohio Medicaid (which does not cover it for insomnia), manufacturer cash-pay assistance, or a compounded version from a licensed 503A pharmacy. Each pathway has a materially different price, and none of the specific dollar amounts quoted below are guaranteed to be current, since manufacturer list prices, pharmacy cash prices, and co-pay card terms change without notice. Anyone deciding whether Dayvigo is affordable should verify the live number for their own plan and pharmacy rather than relying on a published figure, including this one.

What Dayvigo costs, and why the number you see may not match

Manufacturer list price and retail cash price are two different numbers, and both are volatile. Eisai, the manufacturer, sets a list price that is not what most patients pay. Retail cash prices vary by pharmacy, by zip code, and by which discount program (GoodRx, RxSaver, a pharmacy's own membership program) is applied at checkout. Reported figures in the low-to-mid hundreds for list price and substantially lower cash prices after discounting are consistent with how branded hypnotics are typically priced, but exact current numbers require checking a live pricing tool or calling an Ohio pharmacy directly; publishing a specific dollar figure as fact would misstate a number that shifts month to month.

The FDA-approved label recommends starting at 5 mg nightly, with an increase to 10 mg based on clinical response and tolerability (per the FDA-approved prescribing information). Both tablet strengths are typically priced similarly at retail, so a dose increase does not necessarily change the monthly cost, though this should be confirmed with the dispensing pharmacy.

Does Ohio Medicaid cover Dayvigo?

As a general pattern, state Medicaid preferred drug lists treat newer branded hypnotics like Dayvigo as non-preferred, usually requiring documented failure of one or more generic agents (zolpidem, low-dose doxepin, trazodone) before considering a DORA, if the DORA is on the formulary at all for insomnia. Whether Ohio Medicaid's fee-for-service formulary or a specific managed care plan (CareSource, Molina, Buckeye, UnitedHealthcare Community Plan) currently covers Dayvigo for insomnia, and under what prior authorization criteria, is a fact that changes with formulary updates and should be confirmed directly with the Ohio Department of Medicaid or the member's managed care plan rather than assumed from this page. A prescriber can submit a prior authorization request citing clinical necessity regardless of the published formulary position.

Commercial insurance: the general pattern

Most commercial insurers place newer hypnotics like Dayvigo on a non-preferred or higher formulary tier and require prior authorization. Typical criteria seen across payers nationally include a documented insomnia disorder diagnosis, a trial and failure of (or contraindication to) a generic hypnotic, and sometimes an attestation that non-drug options such as cognitive behavioral therapy for insomnia (CBT-I) have been considered. The American Academy of Sleep Medicine's clinical practice guideline recommends CBT-I as first-line therapy for chronic insomnia, with medication reserved for patients who do not respond adequately or who need short-term treatment; insurers commonly cite guidelines of this kind when structuring step-therapy rules, though the exact wording of Ohio-specific payer policies (Anthem, Medical Mutual, SummaCare, UnitedHealthcare, and others) should be confirmed with the member's plan documents, since tiers and co-pay ranges are reset annually and vary by employer group.

How the Eisai savings card generally works

Eisai has offered a manufacturer co-pay assistance program for Dayvigo that is restricted to patients with commercial insurance; patients on Medicare, Medicaid, Tricare, or other government-funded coverage are not eligible, which is standard for manufacturer co-pay cards under federal anti-kickback rules. The card is typically applied as a secondary payer at the pharmacy after the primary insurance adjudicates the claim. Program terms, including the maximum annual or per-fill benefit, are set by the manufacturer and are updated periodically, so the current benefit cap should be confirmed on the manufacturer's program page or with the prescriber's office before assuming a specific out-of-pocket amount. Patients on high-deductible health plans should also ask their insurer whether an accumulator adjustment program applies, since some plans do not count manufacturer co-pay assistance toward the deductible or out-of-pocket maximum even when the card reduces what is charged at the register.

Compounded lemborexant in Ohio: what is and is not established

Under federal law, 503A compounding pharmacies may prepare a compounded medication based on a valid, patient-specific prescription when a prescriber determines that the commercially available product does not meet a particular patient's clinical needs, for example a non-standard dose or an inability to swallow tablets, as established under federal compounding law. Ohio licenses and inspects 503A pharmacies through the Ohio Board of Pharmacy, and compounding within Ohio operates under this same federal framework; there is no Ohio-specific carve-out that would make compounded lemborexant categorically different from compounding any other prescription drug. A 503A pharmacy cannot compound and stock lemborexant in advance without individual prescriptions.

What compounded lemborexant costs varies by pharmacy and is not standardized, and unlike the FDA-approved tablet, a compounded preparation has not been through FDA review for safety, efficacy, or manufacturing consistency for this specific use. Patients considering a compounded version should confirm the pharmacy's current Ohio Board of Pharmacy license and ask their prescriber whether a compounded formulation is clinically necessary rather than simply cheaper, since cost alone is not a standard indication for compounding under federal guidance.

What the trial evidence actually supports

Lemborexant's FDA approval in 2019 was based on phase 3 trials, including a study comparing lemborexant with placebo and with extended-release zolpidem in older adults with insomnia disorder, and a longer extension study assessing whether efficacy was sustained and whether rebound insomnia occurred on discontinuation. These trials are commonly referred to as SUNRISE-1 and SUNRISE-2 in the sleep medicine literature. This draft does not carry a verified citation link to the specific papers, because the identifiers available for this rewrite could not be confirmed against the primary literature; before publication, an editor should locate and cite the correct SUNRISE-1 and SUNRISE-2 papers directly from PubMed or the FDA approval package rather than relying on an inherited citation.

What is reasonably established: lemborexant improved sleep onset and maintenance measures compared with placebo in adults with insomnia disorder, including older adults, in FDA-reviewed trials supporting approval. What is plausible but requires the correct citation to state precisely: the specific sample sizes, effect sizes, and duration of the extension data. What is not established by anything in this article: any claim that lemborexant costs less overall than zolpidem when total treatment costs, not just monthly retail price, are considered, since zolpidem's cash price is lower but its FDA label carries specific warnings about complex sleep behaviors and dosing that should be reviewed with a prescriber, as noted in FDA safety communications regarding zolpidem.

Getting Dayvigo through telehealth in Ohio

Ohio permits telehealth evaluation and prescribing of Schedule IV controlled substances, including Dayvigo, by physicians and other authorized prescribers using synchronous audio-video visits, without a separate in-person visit requirement under current state telehealth rules. A telehealth visit does not change the drug's price; it changes access, which may matter for patients in Ohio counties without a local sleep medicine specialist. The prescriber conducting a telehealth visit still needs to document a clinical evaluation sufficient to establish the insomnia diagnosis and rule out contributing conditions such as obstructive sleep apnea or restless legs syndrome, the same standard expected of an in-person visit.

Practical steps for an Ohio patient

• Call the number on your insurance card and ask directly: formulary tier, prior authorization requirement, and step-therapy criteria for Dayvigo specifically, not for the DORA class in general.
• If you have Ohio Medicaid, ask your managed care plan (not just the state fee-for-service list) whether Dayvigo is covered for insomnia and what a prior authorization would require.
• If you have commercial insurance, ask your prescriber's office to check current Eisai savings card eligibility and benefit terms before you fill, since terms change.
• If you are uninsured, get cash-price quotes from at least two or three pharmacies or a discount pricing tool rather than assuming one number applies statewide.
• If a standard tablet does not fit your clinical situation, ask your prescriber whether a licensed 503A compounding pharmacy is appropriate, and confirm that pharmacy's current Ohio license before filling there.
• If cost remains a barrier after checking insurance and the savings card, ask about Eisai's patient assistance program, which is generally aimed at uninsured or underinsured patients meeting income criteria; eligibility rules are set by the manufacturer and should be confirmed directly.

Evidence boundary

Established: Dayvigo (lemborexant) is FDA-approved for insomnia in adults, dosed at 5 mg or 10 mg nightly, classified as Schedule IV. Ohio permits telehealth prescribing of Schedule IV medications under synchronous visit rules. Federal law permits 503A compounding pharmacies to prepare patient-specific compounded medications, and Ohio licenses those pharmacies through its Board of Pharmacy. Manufacturer co-pay cards for branded drugs are, as a rule, restricted to commercially insured patients and unavailable to those on government insurance.

Plausible but not confirmed in this draft: the specific current dollar figures for Dayvigo's list price, average Ohio cash price, and commercial co-pay ranges, all of which move over time and by location and require direct verification rather than a fixed published number.

Not established here: Ohio Medicaid's current, plan-specific coverage decision for Dayvigo in insomnia, which needs to be confirmed with the Ohio Department of Medicaid or the relevant managed care organization rather than assumed from a general Medicaid formulary pattern; and the exact primary trial citations for lemborexant's efficacy data, which need to be re-sourced from PubMed or the FDA approval package before this article is published.

Verification checklist: stable facts versus facts that expire